Recursion Pharmaceuticals

  • The company develops a phenotypic, high-throughput drug-screening platform to identify drug targets for genetic diseases, inflammatory diseases, immunologic diseases, infectious diseases, and more
  • The value of the company's platform lies in its flexibility and scalability (Chris said the platfo...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email Thank you!

Related Research


Company Snapshot | September 24, 2021

The company was founded by James Sas, Michelle Longmire, Perry Robinson, and Tim Smith in 2015. To date, the company has raised about $202.6 million over six rounds of funding, most recently raising a Series C round in April 2021. Among its investors, we emphasize Sapphire Ventures and GSR Ventures... Not part of subscription

Is it time for AI for drug discovery as a service?

Case Study | October 25, 2021

Despite the value of AI to the pharmaceutical industry in the drug discovery space, significant barriers to its adoption remain. One of the major barriers lies in developing the relevant AI capabilities to tackle questions around novel target identification, lead identification and optimization, ... Not part of subscription

Amalgam Rx

Company Profile | December 13, 2021

Amalgam Rx is a developer of a software‑as‑a‑service (SaaS)‑based technology platform that enables the development, deployment, and scaling of digital therapeutics and health service applications such as electronic health record (EHR) integration, clinical decision support, and clinical trial ... To read more, click here.